Alzheimer’s Protein | CAR T-Cells | Checkpoint Inhibitors, Cancer Information Highlights, 04/13/2022

National Cancer Institute sent this bulletin at 04/13/2022 11:14 AM EDT

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights

From the National Cancer Institute

Updating you about cancer causes, prevention, screening, treatment, coping, and more

New from NCI
Protein Linked to Alzheimer’s May Help Melanoma Spread to the Brain
		A protein called amyloid beta is infamous as a likely contributor to Alzheimer’s disease. Based on a study in mice, researchers have found that melanoma cells that travel to the brain produce their own supply of amyloid beta and that it is necessary for their survival.
Second CAR T-Cell Therapy Approved for Multiple Myeloma
		The Food and Drug Administration (FDA) has approved a second CAR T-cell therapy for adults with multiple myeloma that has not responded to or has returned after treatment. The approval of ciltacabtagene autoleucel (Carvykti) was based on results from a small clinical trial.
New Checkpoint Inhibitor Approved for Advanced Melanoma An immunotherapy treatment called Opdualag is the first new immune checkpoint inhibitor approved by FDA in 8 years. Learn more about this treatment which combines relatlimab and nivolumab (Opdivo) and targets proteins that help stop the immune system from mounting a strong response against cancer cells.
Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Researchers have developed tiny beads that produce an immune-boosting substance called interleukin-2 (also known as IL-2). IL-2 is often given through an IV, reaching the entire body, and can cause severe side effects. When implanted in mice, the beads delivered IL-2 near the tumors while keeping blood levels of IL-2 low.
PDQ Updates
Childhood Non-Hodgkin Lymphoma (NHL) Treatment Our page on treatment of childhood NHL has had a major revision. It includes updated descriptions of the main types of childhood NHL, signs and symptoms, and treatment options. We’ve also updated the treatments used for the different types of childhood NHL.
Soft Tissue Sarcoma Treatment We’ve updated our page on soft tissue sarcoma with major revisions to all sections of the page.
FDA Approvals
Axicabtagene Ciloleucel We’ve updated our axicabtagene ciloleucel (Yescarta) drug summary with an expanded FDA approval. It is now approved to treat adults with diffuse large B-cell lymphoma (DLBCL) that did not respond to first-line immunotherapy or that came back within 1 year of initial immunotherapy.

Also of Interest
Managing Costs and Medical Information Cancer treatment can be very expensive, even when you have insurance. And keeping track of expenses can feel overwhelming. This page suggests ways to help you keep track of tests and treatments, paperwork, and other records.
Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm This updated page describes how treatment for oropharyngeal cancer has evolved over the last several decades to be less intense without risking the cancer coming back. Learn about important clinical trials that helped advance treatment, as well as future research directions.
Contact Us for Help Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions \| Help